Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Rimegepant for Chronic Migraine Prevention in Adolescents
jRCT2051240163Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Nov 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine comparing Rimegepant 75 mg ODT with Placebo ODT (2 arms). Primary endpoint: Change in migraine days per month. Started Nov 2024; status: recruiting.
02
Drugs
rimegepant
03
Conditions
chronic migraine
Beyond the preview
Go deeper on jRCT2051240163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240163.